ES2138648T3 - Derivados de 1h-indol-3-acetamidas como inhibidores de spla2. - Google Patents

Derivados de 1h-indol-3-acetamidas como inhibidores de spla2.

Info

Publication number
ES2138648T3
ES2138648T3 ES94302666T ES94302666T ES2138648T3 ES 2138648 T3 ES2138648 T3 ES 2138648T3 ES 94302666 T ES94302666 T ES 94302666T ES 94302666 T ES94302666 T ES 94302666T ES 2138648 T3 ES2138648 T3 ES 2138648T3
Authority
ES
Spain
Prior art keywords
derivatives
acetamides
indol
spla2 inhibitors
spla2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94302666T
Other languages
English (en)
Spanish (es)
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
Robert Bell Hermann
Richard Walter Schevitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2138648T3 publication Critical patent/ES2138648T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES94302666T 1993-04-16 1994-04-14 Derivados de 1h-indol-3-acetamidas como inhibidores de spla2. Expired - Lifetime ES2138648T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4862993A 1993-04-16 1993-04-16
US20872194A 1994-03-15 1994-03-15

Publications (1)

Publication Number Publication Date
ES2138648T3 true ES2138648T3 (es) 2000-01-16

Family

ID=26726342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94302666T Expired - Lifetime ES2138648T3 (es) 1993-04-16 1994-04-14 Derivados de 1h-indol-3-acetamidas como inhibidores de spla2.

Country Status (25)

Country Link
US (1) US5684034A (enExample)
EP (1) EP0620215B1 (enExample)
JP (1) JPH0725850A (enExample)
KR (1) KR100317755B1 (enExample)
CN (1) CN1068588C (enExample)
AT (1) ATE183503T1 (enExample)
AU (1) AU676884B2 (enExample)
BR (1) BR9401482A (enExample)
CA (1) CA2121323A1 (enExample)
CO (1) CO4230092A1 (enExample)
CZ (1) CZ289750B6 (enExample)
DE (1) DE69420068T2 (enExample)
DK (1) DK0620215T3 (enExample)
ES (1) ES2138648T3 (enExample)
FI (1) FI941767L (enExample)
GR (1) GR3031783T3 (enExample)
HU (1) HUT70836A (enExample)
IL (1) IL109311A0 (enExample)
NO (1) NO300732B1 (enExample)
NZ (1) NZ260298A (enExample)
PL (1) PL181319B1 (enExample)
RU (1) RU2162463C2 (enExample)
TW (1) TW268942B (enExample)
UA (1) UA44218C2 (enExample)
YU (1) YU20194A (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US6252084B1 (en) 1994-03-15 2001-06-26 Eli Lilly And Company 1H-indole-3-acetamide sPLA2 inhibitors
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
JP2000516958A (ja) * 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US6569539B2 (en) 1996-10-30 2003-05-27 Tetra Level Holdings & Finance S.A. Gas barrier packaging laminate method for production thereof and packaging containers
US6713645B1 (en) * 1996-10-30 2004-03-30 Eli Lilly And Company Substituted tricyclics
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EE200000522A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ID27280A (id) * 1998-02-25 2001-03-22 Genetics Inst Inhibitor-inhibitor dari enzim-enzim fosfolipase
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
BR9909345A (pt) 1998-03-31 2000-12-12 Shionogi & Co Pirrolo [1,2-a] pirazina inibidor de spla2
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
IL129484A0 (en) * 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
KR20010034881A (ko) 1998-05-21 2001-04-25 시오노 요시히코 ｓＰＬＡ2 억제 효과를 갖는 피롤로[1,2-ｂ]피리다진 유도체
JP2002522386A (ja) * 1998-08-03 2002-07-23 イーライ・リリー・アンド・カンパニー インドールｓＰＬＡ２インヒビター
CA2338855A1 (en) 1998-08-03 2000-02-17 Eli Lilly And Company Indole spla2 inhibitors
WO2000010568A1 (en) 1998-08-24 2000-03-02 Draheim Susan E Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase a¿2?
DE69931963D1 (de) * 1998-10-14 2006-07-27 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
EP1140943B1 (en) * 1998-12-22 2003-08-13 Eli Lilly And Company Substituted pyrroloindoles
DE60032774D1 (de) * 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
AU6023200A (en) 1999-08-02 2001-02-19 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
WO2001021587A2 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
WO2001036420A1 (en) 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an spla2- inhibiting effect
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2002000646A1 (en) * 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
WO2002000256A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
US20050203166A1 (en) * 2000-06-30 2005-09-15 Cancer Research Technology Limited Indole-3-acetic acid derivatives
GB0016162D0 (en) * 2000-06-30 2000-08-23 Cancer Res Campaign Tech Indole-3-acetic acid derivatives
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
AU2001282410A1 (en) * 2000-08-24 2002-03-22 Dublin City University N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
CA2431506A1 (en) 2000-12-18 2002-07-25 Eli Lilly And Company Benz(g) indoles and their use as spla2 inhibitors
CA2430808A1 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
TWI314457B (enExample) * 2001-03-19 2009-09-11 Shionogi & Co
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
JP2007527397A (ja) * 2003-07-01 2007-09-27 マイクロバイア インコーポレイテッド Ｃｏｘ−２及びｆａａｈ阻害剤
US20070293542A1 (en) * 2003-10-16 2007-12-20 Cali Brian M Selective Cox-2 Inhibitors
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20050234244A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Synthesis of COX-2 and FAAH inhibitors
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
US20070203209A1 (en) * 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
EP1948602A2 (en) * 2005-11-03 2008-07-30 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN105384619B (zh) * 2014-08-22 2020-05-29 四川海思科制药有限公司 一种异丙基苯酚衍生物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2890223A (en) * 1956-03-22 1959-06-09 Research Corp 1-benzyl, 2-methyl, 5-methoxy tryptamine
US3242162A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3242193A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3196162A (en) * 1961-03-13 1965-07-20 Merck & Co Inc Indolyl aliphatic acids
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
US4428962A (en) * 1981-10-30 1984-01-31 Schering Corporation Indoles in treatment of peptic ulcers
WO1988005432A1 (fr) * 1987-01-23 1988-07-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose de 5-hydroxyindole-3-carboxamide et son usage en medecine
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Also Published As

Publication number Publication date
CZ289750B6 (cs) 2002-03-13
NO300732B1 (no) 1997-07-14
GR3031783T3 (en) 2000-02-29
US5684034A (en) 1997-11-04
DE69420068T2 (de) 1999-12-23
IL109311A0 (en) 1994-07-31
HUT70836A (en) 1995-11-28
DK0620215T3 (da) 1999-12-06
AU676884B2 (en) 1997-03-27
RU2162463C2 (ru) 2001-01-27
CZ89394A3 (en) 1994-12-15
CO4230092A1 (es) 1995-10-19
FI941767A0 (fi) 1994-04-15
CA2121323A1 (en) 1994-10-17
PL181319B1 (pl) 2001-07-31
TW268942B (enExample) 1996-01-21
NO941361D0 (no) 1994-04-15
EP0620215A1 (en) 1994-10-19
NO941361L (no) 1994-10-17
CN1068588C (zh) 2001-07-18
KR100317755B1 (ko) 2002-08-09
JPH0725850A (ja) 1995-01-27
BR9401482A (pt) 1994-10-18
EP0620215B1 (en) 1999-08-18
YU20194A (sh) 1997-09-30
DE69420068D1 (de) 1999-09-23
HU9401060D0 (en) 1994-07-28
UA44218C2 (uk) 2002-02-15
FI941767A7 (fi) 1994-10-17
FI941767L (fi) 1994-10-17
AU5949294A (en) 1994-10-20
CN1098715A (zh) 1995-02-15
NZ260298A (en) 1996-05-28
ATE183503T1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
AU676884B2 (en) 1H-indole-3-acetamide sPLA2 inhibitors
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
ES2128510T3 (es) Hidracidas del acido 1h-indol-3-acetico inhibidoras de spla2.
RU94012931A (ru) Гидразиды 1н-индол-3-уксусной кислоты как ингибиторы spla2
UY24154A1 (es) Preparacion del acido clavulanico con ayuda de ciertas poliaminas
BG101422A (bg) Бензоксазолни производни като бронхоразширяващи средства
ES8506677A1 (es) Un procedimiento para la preparacion de nuevos derivados de 8-cloro71,5-benzotiazepina.
ECSP034848A (es) Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes
RU94012930A (ru) Новые 1-н-индол-3-ацетамиды как ингибиторы spla2 и фармацевтическая композиция на их основе
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
ECSP093680A (es) Proceso para derivados del acido fenilacetico
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
ES8203376A1 (es) Procedimiento para obtener acidos 6-cloro- o 6-bromo-1,2-di-hidro-3h-pirrolo(1,2-a)pirrol-1-carboxilicos y sus derivados
ES2195182T3 (es) Fenil glioxamidas como inhibidores de spla2.
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2
ES2191683T3 (es) Procedimiento para preparar inhibidores de la proteasa del vih.
BR0013751A (pt) Processo para produção de derivados de ácido naftiridina-3-carboxìlico
NZ503880A (en) Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
ES2006361A6 (es) Un procedimiento para preparar derivados de insoindolinilo opticamente activos.
ES8506601A1 (es) Un procedimiento para la preparacion de derivados de benzamida
ES2120483T3 (es) Alcoholes benzilo y benzhidrilo.
MX9300260A (es) Pirrolilbenzodiacepinonas, procedimiento para su preparacion y medicamento que las contiene.
NO883486D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
ES8704495A1 (es) Un procedimiento para la preparacion de un derivado tetraci-clico de espirohidantoina biologicamente activo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 620215

Country of ref document: ES